Termination of option to purchase agreement.
Posted on 11-5-2017
Tampa, FL. October 20, 2017. Ultroid, LLC, Ultroid Marketing Development Corp. & Ultroid Technology (collectively “The Ultroid Group”) today confirmed that they have terminated the Option to Purchase Agreement with Dragon Jade International, Ltd. (“Dragon Jade”), effective Sept.28, 2017.
The Ultroid Group notifies, simultaneously with this announcement that all affiliates, business partners, contractors, etc. and their respective assigns are that Dragon Jade and it representative have no authority to negotiate, contract for, receive information concerning or otherwise bind The Ultroid Group in anyway and that any such authority that may have been given expressly or implied is hereby terminated. Please contact us directly with any questions or concerns.
Ultroid Technologies, Inc. manufactures and markets the Ultroid® Hemorrhoid Management System (“Ultroid® System”). The Ultroid® System, which is FDA cleared and also approved for use in many other nations, is a non-surgical, non-anesthetic, and rapid treatment for hemorrhoid disease (HD).
The Ultroid® System is covered by most major insurers and Medicare, and has been successfully utilized in an estimated 180,000 procedures, by several hundred physicians, practices, clinics, and surgical centers. The Ultroid® procedure has been used in over 150 clinics in the US and was introduced in UK in 2013 where it is currently offered in 15 clinics.
THE ULTROID GROUP
Michael J. Goeree, Chairman, CEO & President
Michael A. Knox, CPA, Director, Exec. VP & CFO
2919 W. Swann Avenue